SuperworthMedline forward PE MDLN
Share price divided by analysts' consensus earnings for the next twelve months, since 2025.
- Today, Oct 23, 2026
- 23.2×
- Peer median
- 29.2×
Medline's forward PE is 23.2× as of Oct 23, 2026.
It has traded since Dec 19, 2025, and over that time its forward PE ranged from 21.5× in Sep 2026 to 38.5× in Feb 2026.
The median for 10 medical instruments and supplies stocks of a similar size is 29.2×.
Forward PE over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 23.2× | 21.5× | 38.5× |
| 2025 | 35.9× | 33.9× | 35.9× |
Against its peers
Companies in Medical - Instruments & Supplies nearest Medline's size, closest first, today.
| Company | Forward PE |
|---|---|
| MDLNMedline | 23.2× |
| BDXBecton, Dickinson and | 15.1× |
| RMDResMed | 20.8× |
| WSTWest Pharmaceutical Services | 42.2× |
| SOLVSolventum | n/m |
| PENPenumbra | n/m |
| ISRGIntuitive Surgical | 37.5× |
| COOCooper Companies | n/m |
| ALGNAlign Technology | n/m |
| GMEDGlobus Medical | n/m |
| PODDInsulet | n/m |
| Peer median | 29.2× |
Where Medline ranks
What the forward PE tells you
Price divided by what analysts expect the company to earn over the next twelve months. It answers "what am I paying for next year" instead of last year.
Estimates are opinions. When forward PE is far below trailing PE, analysts expect a big jump in earnings. If that jump slips, the stock was not as cheap as it looked.
More on Medline
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.